Gemini Therapeutics is a clinical stage company developing precision medicine for age-related macular degeneration. Their lead candidate GEM103 is a treatment for dry AMD patients and they also have GEM307 for systemic diseases. The company, founded in 2015, is based in Cambridge, Massachusetts.